Ken Fisher's HAE Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 662.5K shares of Haemonetics Corporation (HAE) worth $32.29 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in HAE, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2021, adding 946.1K shares. Largest reduction occurred in Q1 2023, reducing 207.9K shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Haemonetics Corporation (HAE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Haemonetics Corporation (HAE) Trades by Ken Fisher
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +169,246 | Add 0.00% | 169,245 | $41.35 |
| Q4 2013 | -21,250 | Reduce 12.56% | 147,995 | $42.13 |
| Q1 2014 | -550 | Reduce 0.37% | 147,445 | $32.59 |
| Q2 2014 | +30,200 | Add 20.48% | 177,645 | $35.28 |
| Q4 2014 | +16,600 | Add 9.34% | 194,245 | $37.42 |
| Q2 2015 | -4,725 | Reduce 2.43% | 189,520 | $41.36 |
| Q3 2015 | +19,400 | Add 10.24% | 208,920 | $32.32 |
| Q4 2015 | +10,190 | Add 4.88% | 219,110 | $32.24 |
| Q1 2016 | +17 | Add 0.01% | 219,127 | $34.20 |
| Q2 2016 | +38,340 | Add 17.50% | 257,467 | $30.42 |
| Q3 2016 | +10,245 | Add 3.98% | 267,712 | $36.21 |
| Q4 2016 | -45 | Reduce 0.02% | 267,667 | $40.20 |
| Q1 2017 | -25,700 | Reduce 9.60% | 241,967 | $40.57 |
| Q2 2017 | -420 | Reduce 0.17% | 241,547 | $39.49 |
| Q3 2017 | +1,728 | Add 0.72% | 243,275 | $44.87 |
| Q4 2017 | -17,636 | Reduce 7.25% | 225,639 | $58.08 |
| Q1 2018 | -6,528 | Reduce 2.89% | 219,111 | $73.16 |
| Q2 2018 | -13,347 | Reduce 6.09% | 205,764 | $89.68 |
| Q3 2018 | -77,118 | Reduce 37.48% | 128,646 | $114.58 |
| Q4 2018 | +114,078 | Add 88.68% | 242,724 | $100.05 |
| Q1 2019 | +28,855 | Add 11.89% | 271,579 | $87.48 |
| Q2 2019 | -36,273 | Reduce 13.36% | 235,306 | $120.34 |
| Q3 2019 | +2,482 | Add 1.05% | 237,788 | $126.14 |
| Q4 2019 | -48,817 | Reduce 20.53% | 188,971 | $114.90 |
| Q1 2020 | -12,124 | Reduce 6.42% | 176,847 | $99.66 |
| Q2 2020 | -7,926 | Reduce 4.48% | 168,921 | $89.56 |
| Q3 2020 | -14,207 | Reduce 8.41% | 154,714 | $87.25 |
| Q4 2020 | -580 | Reduce 0.37% | 154,134 | $118.75 |
| Q1 2021 | -1,507 | Reduce 0.98% | 152,627 | $111.01 |
| Q2 2021 | +946,106 | Add 619.88% | 1.1 M | $66.64 |
| Q3 2021 | +4,160 | Add 0.38% | 1.1 M | $70.59 |
| Q4 2021 | +91,752 | Add 8.32% | 1.19 M | $53.04 |
| Q1 2022 | -6,487 | Reduce 0.54% | 1.19 M | $63.22 |
| Q2 2022 | +81,616 | Add 6.87% | 1.27 M | $65.18 |
| Q3 2022 | -22,231 | Reduce 1.75% | 1.25 M | $74.03 |
| Q4 2022 | -140,846 | Reduce 11.29% | 1.11 M | $78.65 |
| Q1 2023 | -207,869 | Reduce 18.78% | 898,828 | $82.75 |
| Q2 2023 | +3,916 | Add 0.44% | 902,744 | $85.14 |
| Q3 2023 | -40,124 | Reduce 4.44% | 862,620 | $89.58 |
| Q4 2023 | -150,953 | Reduce 17.50% | 711,667 | $85.51 |
| Q1 2024 | -13,627 | Reduce 1.91% | 698,040 | $85.35 |
| Q2 2024 | -4,986 | Reduce 0.71% | 693,054 | $82.73 |
| Q3 2024 | -3,545 | Reduce 0.51% | 689,509 | $80.38 |
| Q4 2024 | +22,265 | Add 3.23% | 711,774 | $78.08 |
| Q1 2025 | +22,769 | Add 3.20% | 734,543 | $63.55 |
| Q2 2025 | -45,401 | Reduce 6.18% | 689,142 | $74.61 |
| Q3 2025 | -26,638 | Reduce 3.87% | 662,504 | $48.74 |
Ken Fisher's Haemonetics Corporation Investment FAQs
Ken Fisher first purchased Haemonetics Corporation (HAE) in Q2 2013, acquiring 169,245 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Haemonetics Corporation (HAE) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher's largest addition to Haemonetics Corporation (HAE) was in Q2 2021, adding 1,098,733 shares worth $73.22 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 662,504 shares of Haemonetics Corporation (HAE), valued at approximately $32.29 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Haemonetics Corporation (HAE) represents approximately 0.01% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher's peak holding in Haemonetics Corporation (HAE) was 1,269,774 shares, as reported at the end of Q2 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.